CLINICAL_TRIALS ClinicalTrials.gov record update

Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05996263
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:17.665436+00:00
Published At: 2024-08-09T00:00:00+00:00
Record Updated At: 2024-08-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lung Cancer Stage III", "Lung Cancer Stage IV"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-08-09"
protocolSection.identificationModule.nctId: "NCT05996263"
protocolSection.identificationModule.officialTitle: "Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 \u2265 50% Treated With Pembrolizumab."
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.